Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linked

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Apr 2022: Trial registered, NCT05335876
  2. 19 Dec 2022: Trial started, NCT05335876

The trials

NCT05335876: Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

State
Under way
Phase
Phase 3
People
20 taking part
Started
19 Dec 2022
Primary completion
29 Apr 2031
Arms
Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec
Results
None posted
  1. 20 Apr 2022: Trial registered
  2. 19 Dec 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Onasemnogene Abeparvovec-xioi, Zolgensma.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.